Canada Markets close in 3 hrs 53 mins

Windtree Therapeutics, Inc. (WINT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6600+0.0700 (+4.40%)
As of 12:02PM EST. Market open.
Sign in to post a message.
  • M
    Missy
    WINT will have it's moment, but it will take time and patients is required. I am in for the long haul.
  • L
    Linda
    Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that on Tuesday, October 19, 2021 at 8:00 am Eastern Time it will host a Key Opinion Leader (KOL) webinar on istaroxime for the treatment of acute heart failure and the upcoming data in early cardiogenic shock.

    The webinar will feature a presentation by KOL John Teerlink, M.D., University of California-San Francisco, who will discuss the current treatment landscape and unmet medical need in treating patients with acute heart failure and the potential role for istaroxime, the company's product candidate, a first-in-class, dual action, agent in clinical development for the treatment of acute decompensated heart failure (ADHF).
    The speaker at this seminar that was videoed said something that wasn't good about one of the drugs they sell...

    Windtree's management team will also discuss the clinical development program for istaroxime, which has been studied in two Phase 2 clinical trials to date. Additionally, Windtree will discuss its development program for istaroxime in early cardiogenic shock, which is currently in a Phase 2 study with targeted completion in Q4 2021. The article was from the 14th I think... but it just came out today...
  • s
    stephen
    Craig Fraser ceo just bought 3000 shares directly
  • s
    stephen
    October 12, 2021 7:30 AM EDT
    Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study
  • M
    Missy
    All of the analysts and finance writers are very optimistic about the future of WINT and their lead drug candidates and I agree with their assessment. Entering into a high value market for heart failure.
  • s
    stephen
    Anyone else thinks this drop is fake?
  • h
    haythamdrissi
    Can someone explain why this stock used to be like 50k +?
  • B
    BullCall56
    Aren't they going to need to raise capital?
  • w
    wilfredo
    Good news today; excellent work
  • J
    James
    buy on the rumor sell on the news
  • J
    James
    bought more again today
  • W
    Wade
    Huge potential here in the very near term. Looking for more than a 200% return in the coming weeks.
  • s
    stephen
    October 25, 2021 7:30 AM EDT
    Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
  • J
    James
    It may be a waste of money but I'll take that chance. RISK/REWARD.
  • M
    Marc
    for those that believe, this was a buying op.
    5000 added, because the media triggered some holder to crash wint to buy in lower.
    so typical of hedge traders.
  • M
    Marc
    manipulation to trigger stop loss n buy in lower.
    what else changed???
    n
  • J
    James
    Long shot but worth the investment .
  • J
    James
    I bought many shares yesterday.
  • s
    stephen
    Gonna pop
  • s
    stephen
    Only got 2334 @ 2.32 but more than happy to average down on this stock. So much in their pipeline